The multiple paths towards MET receptor addiction in cancer.

Oncogene 2018 06 19;37(24):3200-3215. Epub 2018 Mar 19.

Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of Tumorigenesis and Targeted Therapies, F-59000, Lille, France.

Targeted therapies against receptor tyrosine kinases (RTKs) are currently used with success on a small proportion of patients displaying clear oncogene activation. Lung cancers with a mutated EGFR provide a good illustration. The efficacy of targeted treatments relies on oncogene addiction, a situation in which the growth or survival of the cancer cells depends on a single deregulated oncogene. MET, a member of the RTK family, is a promising target because it displays many deregulations in a broad panel of cancers. Although clinical trials having evaluated MET inhibitors in large populations have yielded disappointing results, many recent case reports suggest that MET inhibition may be effective in a subset of patients with unambiguous MET activation and thus, most probably, oncogene addiction. Interestingly, preclinical studies have revealed a particularity of MET addiction: it can arise through several mechanisms, and the mechanism involved can differ according to the cancer type. The present review describes the different mechanisms of MET addiction and their consequences for diagnosis and therapeutic strategies. Although in each cancer type MET addiction affects a restricted number of patients, pooling of these patients across all cancer types yields a targetable population liable to benefit from addiction-targeting therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0185-4DOI Listing
June 2018
2 Reads

Publication Analysis

Top Keywords

met addiction
12
oncogene addiction
8
met
8
cancer type
8
addiction
6
cancer
5
case reports
4
disappointing case
4
large populations
4
populations yielded
4
yielded disappointing
4
reports met
4
effective subset
4
unambiguous met
4
met activation
4
activation oncogene
4
patients unambiguous
4
subset patients
4
inhibition effective
4
inhibitors large
4

References

(Supplied by CrossRef)

B Vogelstein et al.
Science 2013

IB Weinstein et al.
Science 2002

SG O’Brien et al.
New Engl J Med 2003

R Rosell et al.
Lancet Oncol 2012

J Baselga et al.
J Clin Oncol 2005

M Olivero et al.
Br J Cancer 1996

E Ichimura et al.
Jpn J Cancer Res 1996

S Park et al.
Histol Histopathol 2012

DR Spigel et al.
J Clin Oncol 2017

G Scagliotti et al.
J Clin Oncol 2015

C Birchmeier et al.
Nat Rev Mol Cell Biol 2003

Similar Publications